Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

20.28
-0.9300-4.38%
Post-market: 20.280.00000.00%17:03 EDT
Volume:734.65K
Turnover:15.08M
Market Cap:2.54B
PE:-6.16
High:21.68
Open:21.31
Low:20.24
Close:21.21
52wk High:26.40
52wk Low:6.50
Shares:125.35M
Float Shares:88.65M
Volume Ratio:0.44
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2900
EPS(LYR):-3.2900
ROE:-63.26%
ROA:-21.08%
PB:4.03
PE(LYR):-6.16

Loading ...

Arcus reports 15.1-month median PFS for casdatifan in late-line kidney cancer ARC-20 study

Reuters
·
Feb 24

Arcus Biosciences to Present Casdatifan Phase 1/1b ARC-20 Kidney Cancer Data at ASCO GU Cancer Symposium

Reuters
·
Feb 24

Wells Fargo Downgrades Arcus Biosciences to Equal Weight From Overweight, Adjusts PT to $23 From $30

MT Newswires Live
·
Feb 12

Arcus Biosciences Inc : Wells Fargo Cuts to Equal Weight From Overweight

THOMSON REUTERS
·
Feb 12

Wells Fargo downgrades Arcus Biosciences (RCUS) to a Hold

TIPRANKS
·
Feb 12

Arcus Biosciences Inc. to Host Conference Call on Financial Results and Pipeline Update

Reuters
·
Feb 12

Arcus Biosciences Grants Stock Options and Restricted Stock Units to New Employees

Reuters
·
Jan 27

Arcus’ 2026 Oncology Readouts And Phase 3 Progress Might Change The Case For Investing In RCUS

Simply Wall St.
·
Jan 17

Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs

TIPRANKS
·
Jan 13

Arcus Biosciences Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Jan 08

BRIEF-Arcus Outlines Plans For Casdatifan And Its Inflammation Programs

Reuters
·
Jan 08

Arcus Biosciences Inc - Plans Three Data Readouts for Casdatifan in 2026

THOMSON REUTERS
·
Jan 08

Arcus Biosciences Inc - Expects to Fund Operations Until Second Half of 2028

THOMSON REUTERS
·
Jan 08

Arcus Biosciences President Juan C. Jaen Reports Sale of Common Shares

Reuters
·
Jan 08

Arcus Biosciences CFO Robert C. Goeltz II Reports Disposal of Common Shares

Reuters
·
Jan 03

Have Insiders Sold Arcus Biosciences Shares Recently?

Simply Wall St.
·
Dec 20, 2025

Arcus Biosciences President Juan C. Jaen Reports Sale of Common Shares

Reuters
·
Dec 19, 2025

Arcus Biosciences Inc - First Amendment Extends Maturity Date to Sept 1, 2030, With No Further Extension Right- SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Arcus Biosciences Inc - Amendment Changes Terms for $150 Mln Loan Commitments - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Arcus Biosciences Amends Loan Agreement to Access Up to $150 Million in New Financing

Reuters
·
Dec 19, 2025